Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Spain
Clinical trial register · Spain

Clinical Trials in Spain

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5909 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:19 UTC
5909
Studies in scope
all four open statuses
3100
Recruiting now
open to new participants
1129
Lead sponsors
across recruiting studies
Top sites
Barcelona 83 Madrid 68 Seville 38 Valencia 33 A Coruña 19
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca221 Novartis Pharmaceuticals151 Merck Sharp & Dohme LLC133 Janssen Research & Development, LLC125 Hoffmann-La Roche118 AbbVie103 Eli Lilly and Company102 Pfizer82 Bristol-Myers Squibb79 Sanofi67 GlaxoSmithKline66 University of Valencia64 Amgen54 Boehringer Ingelheim53 Hospital Universitari Vall d'Hebron Research Institute48 Novo Nordisk A/S43 Universidad Complutense de Madrid40 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau39 Hospital Clinic of Barcelona39 Takeda38 Regeneron Pharmaceuticals38 Daiichi Sankyo34 Gilead Sciences33 Universidad de Granada32 Bayer32 Show all 1646 Clear sponsor filter
Site location
Barcelona83 Madrid68 Seville38 Valencia33 A Coruña19 Málaga19 Esplugues de Llobregat13 Ferrol13 Córdoba11 Santiago de Compostela10 Granada10 Pamplona9 Badajoz9 Badalona9 Pozuelo de Alarcón8 Centelles8 Hospitalet7 Santander7 Oviedo6 León6 Lleida6 Almería6 Alzira6 Salamanca5 Las Palmas de Gran Canaria5 Show all 81
All 81 locations
Target enrolment
to

Trials in this register

102 of 5909 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Eli Lilly and Company
Phase 3
3,000
A Coruña, Alzira, Ferrol, Granada, Lugo, Madrid, Majadahonda, Palma
2026-12
Not yet open
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258Endometrial Neoplasms, Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Carcinoma, Non-Small-Cell Lung
DrugSofe-M
Eli Lilly and Company
Phase 1
370
Barcelona, Madrid
2026-12
Not yet open
Eli Lilly and Company
Phase 2
330
Alcorcón, Barcelona, Madrid, Salamanca, Valdemoro, Vigo, Zamora
2026-11
Recruiting
Eli Lilly and Company
Phase 3
1,000
A Coruña, Alzira, Barcelona, Ferrol, Granada, Málaga, Seville
2026-10-16
Not yet open
Eli Lilly and Company
Phase 2
50
Barcelona, Jaén, Madrid, Santa Cruz de Tenerife, Santander, Santiago de Compostela
2026-10
Recruiting
Eli Lilly and Company
Phase 3
150
Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz
2026-09-25
Recruiting
Eli Lilly and Company
Phase 3
2,001
Alcobendas, Barcelona, Centelles, Ferrol, Granada, Madrid, Pozuelo de Alarcón, Seville
2026-08-26
Recruiting
Eli Lilly and Company
Phase 3
1,000
Barcelona, Centelles, Madrid, Oviedo, Salamanca, Seville, Zamora
2026-08-14
Recruiting
Eli Lilly and Company
Phase 3
170
Barcelona, Málaga, Seville
2026-07-08
Recruiting
Eli Lilly and Company
Phase 3
252
A Coruña, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Seville, Valencia
2026-06-01
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Barcelona, Madrid
2026-05-28
Recruiting
Eli Lilly and Company
Phase 1
32
L'Hospitalet de Llobregat, Valencia
2026-05-14
Recruiting
Eli Lilly and Company
Phase 1
32
L'Hospitalet de Llobregat, Valencia
2026-05-14
Recruiting
Eli Lilly and Company
Phase 2
531
Barcelona, Centelles, Granada, Madrid, Marbella, Salamanca, Santiago de Compostela
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
342
Barcelona, Centelles, Granada, Madrid, Marbella, Salamanca, Santiago de Compostela
2026-04-29
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Barcelona, Madrid
2026-04-17
Recruiting
Eli Lilly and Company
Phase 4
150
Santander, Seville
2026-03-09
Recruiting
Eli Lilly and Company
Phase 3
900
A Coruña, Almería, Barcelona, Ferrol, Palma de Mallorca, Pozuelo de Alarcón, Santander, Seville
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
800
Guadalajara, Lleida, Logroño, Madrid, Málaga, Seville
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Barcelona, Madrid, Oviedo, Salamanca, Zamora
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
300
Barakaldo, Barcelona, Esplugues de Llobregat, Madrid, Santander, Seville, Valencia
2026-02-05
Recruiting
Eli Lilly and Company
Phase 3
150
Barakaldo, Esplugues de Llobregat, Madrid
2026-01-12
Recruiting
Eli Lilly and Company
Phase 3
800
Badajoz, Barcelona, Cáceres, Donostia / San Sebastian, Granada, Hospitalet, Jaén, Las Palmas de Gran Canaria
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
1,035
Alzira, Barcelona, Madrid, Málaga, Santiago de Compostela, Seville
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Badajoz, Badalona, Barakaldo, Barcelona, Córdoba, Elche, Girona, Hospitalet
2025-12-12
Recruiting
Eli Lilly and Company
Phase 3
7,140
Almería, Alzira, Badajoz, Badalona, Barcelona, Boadilla del Monte, Lugo, Majadahonda
2025-12-01
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Barcelona, Madrid, Mataró, Málaga, Reus
2025-11-28
Recruiting
Eli Lilly and Company
Phase 2
252
Barcelona, Fuenlabrada, Gijón, Madrid
2025-11-10
Recruiting
Eli Lilly and Company
Phase 3
1,630
Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
4,500
A Coruña, Badalona, Barcelona, Ferrol, Huelva, Madrid, Palma, Pontevedra
2025-10-15
Active, closed
Eli Lilly and Company
Phase 3
800
A Coruña, Barcelona, Málaga, Santander, Santiago de Compostela, Seville, Valladolid
2025-09-15
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
A Coruña, Barcelona, Centelles, Córdoba, Ferrol, Granada, Huelva, Jaén
2025-09-02
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Barcelona, Madrid
2025-08-06
Recruiting
Eli Lilly and Company
Phase 1
36
L'Hospitalet de Llobregat, Valencia
2025-08-05
Recruiting
Eli Lilly and Company
Phase 1/2
68
Barcelona, Burgos, Murcia, Pamplona
2025-07-30
Active, closed
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
Barcelona, Madrid
2025-07-28
Recruiting
Eli Lilly and Company
Phase 3
350
Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
290
Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia
2025-06-26
Active, closed
Eli Lilly and Company
Phase 3
465
Badajoz, Badalona, Barcelona, Madrid, Seville
2025-05-12
Active, closed
Eli Lilly and Company
Phase 3
487
A Coruña, Barcelona, Centelles, León, Seville
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
A Coruña, Barcelona, Centelles, León, Seville
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
974
A Coruña, Barcelona, Centelles, León, Seville
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
905
A Coruña, Barcelona, Ferrol, Móstoles, Santander, Seville
2025-04-25
Recruiting
Eli Lilly and Company
Phase 3
700
Badajoz, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, Madrid, Málaga, Palma
2025-03-27
Recruiting
Eli Lilly and Company
Phase 3
125
Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz
2024-11-18
By invitation
Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy
NCT06696456Otoferlin Gene-mediated Hearing Loss
Eli Lilly and Company
Observational
30
Esplugues de Llobregat
2024-11-11
Active, closed
Eli Lilly and Company
Phase 2
45
Barcelona, Córdoba, Esplugues de Llobregat, Madrid, Seville, Valencia
2024-10-25
Active, closed
Eli Lilly and Company
Phase 3
1,400
Barcelona, Pozuelo de Alarcón, San Sebastián, Seville
2024-10-24
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab
Eli Lilly and Company
Phase 1
750
Barcelona, Madrid, Málaga
2024-10-21
Active, closed
Eli Lilly and Company
Phase 2
143
Barcelona, Ciudad Real, Córdoba, Huelva, Las Palmas de GC, Madrid, Santiago de Compostela, Seville
2024-10-10
Active, closed
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
Barcelona, Madrid
2024-09-19
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
Barcelona, Madrid
2024-09-12
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
DrugPembrolizumab
Eli Lilly and Company
Phase 1
460
Barcelona, Madrid, Seville
2024-07-01
Recruiting
Eli Lilly and Company
Phase 3
300
Barcelona, Córdoba, Madrid, Málaga, Valencia
2024-06-03
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin
Eli Lilly and Company
Phase 1
575
Barcelona, Madrid, Valencia
2024-05-20
Active, closed
Eli Lilly and Company
Phase 3
10,000
A Coruña, Almería, Alzira, Barcelona, Ferrol, Málaga, Oviedo, Palma de Mallorca
2024-04-30
Recruiting
Eli Lilly and Company
Phase 3
510
Andalucia, Barcelona, Cadiz, Galícia, Madrid, Pamplona
2024-04-29
Recruiting
Eli Lilly and Company
Phase 3
90
Córdoba, Sabadell, Valencia
2024-03-13
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Barcelona, Madrid, Seville
2024-03-05
Active, closed
Eli Lilly and Company
Phase 3
17,300
A Coruña, Alcorcón, Badalona, Barcelona, Córdoba, Denia, El Palmar, Murcia, Ferrol
2024-03-05
Recruiting
Eli Lilly and Company
Phase 3
1,264
A Coruña, Badajoz, Barakaldo, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, León
2023-12-21
Active, closed
Eli Lilly and Company
Phase 3
3,127
A Coruña, Ferrol, Almería, Málaga, Seville, Badalona, Barcelona, Valladolid
2023-06-05
Recruiting
Eli Lilly and Company
Phase 1/2
880
Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Reus, Seville
2023-04-17
By invitation
Eli Lilly and Company
Phase 3
338
Esplugues de Llobregat, Las, Madrid, Pozuelo de Alarcón, Pamplona, Pontevedra, Manises
2023-03-09
Recruiting
Eli Lilly and Company
Phase 3
595
Badalona, Barcelona, Bilbao (Bizkaia), Madrid, Valencia
2023-02-27
Recruiting
Eli Lilly and Company
Phase 1
677
Barcelona, Madrid, Santander
2023-01-12
Active, closed
Eli Lilly and Company
Phase 3
377
Esplugues de Llobregat, Las, Madrid, Pamplona
2022-10-18
Active, closed
Eli Lilly and Company
Phase 3
15,374
A Coruña, Almería, Alzira, Barcelona, Bilbao, Ferrol, Granada, León
2022-10-11
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Barcelona, Lleida, Sant Cugat del Vallès, Valencia
2022-10-10
Active, closed
Eli Lilly and Company
Phase 3
8,000
A Coruña, Alicante, Almería, Badajoz, Barcelona, Bilbao, Burgos, Cáceres
2022-10-04
Active, closed
Eli Lilly and Company
Phase 2
46
Barcelona, Esplugues de Llobregat, Madrid, Seville, Valencia
2022-09-20
Active, closed
Eli Lilly and Company
Phase 1
260
Barcelona, Madrid, Pozuelo de Alarcón, Valencia
2022-05-11
Active, closed
Eli Lilly and Company
Phase 3
925
Hospitalet, Madrid, Valencia, Badajoz, Seville
2022-04-14
Active, closed
Eli Lilly and Company
Phase 3
368
A Coruña, Palma, Barcelona, El Palmar, Málaga, Pamplona, Reus, Valencia
2022-03-11
Active, closed
Eli Lilly and Company
Phase 3
152
Santiago de Compostela, Cadiz, Córdoba, Badalona, Barcelona, L'Hospitalet Del Llobregat, Mataró, León
2021-12-20
Active, closed
Eli Lilly and Company
Phase 3
874
Barcelona, Cáceres, Lleida, Madrid, San Cristóbal de La Laguna, Valencia, Granada, Seville
2021-10-04
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Córdoba, Esplugues de Llobregat, Sabadell, Valencia
2021-05-26
Active, closed
Eli Lilly and Company
Phase 3
101
Esplugues de Llobregat, Madrid, Málaga, Seville, Valencia
2021-04-13
Active, closed
Eli Lilly and Company
Phase 3
312
Barcelona, Seville, Valencia, Valladolid
2020-11-25
Active, closed
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
DrugsLY3410738·Azacitidine·Venetoclax
Eli Lilly and Company
Phase 1
260
Barcelona, Madrid, Valencia
2020-11-19
Active, closed
Eli Lilly and Company
Phase 1
200
Barcelona, Madrid
2020-10-01
Active, closed
Eli Lilly and Company
Phase 1
71
Barcelona, Madrid
2020-06-11
Active, closed
Eli Lilly and Company
Phase 3
261
Palma de Mallorca, Badalona, Santiago de Compostela, Las Palmas de Gran Canaria, Majadahonda, Pamplona, Alicante, Barcelona
2020-02-17
Active, closed
Eli Lilly and Company
Phase 3
58
Esplugues de Llobregat, Madrid, Seville, Valencia
2020-02-12
Recruiting
Eli Lilly and Company
Phase 2
105
Barcelona, Esplugues de Llobregat, Madrid, San Cristóbal de La Laguna, Seville, Valencia
2020-01-22
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Barcelona, Madrid, Valencia
2019-12-10
Active, closed
Eli Lilly and Company
Phase 3
30
Esplugues de Llobregat, Madrid, Valencia
2019-10-16
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
36
Barcelona
2019-06-13
Recruiting
Eli Lilly and Company
Phase 3
190
Esplugues de Llobregat, Madrid, Seville, Valencia
2019-04-05
Active, closed
Eli Lilly and Company
Phase 2/3
393
Barcelona, Hospitalet, Madrid, Málaga
2018-11-26
Active, closed
Eli Lilly and Company
Phase 3
1,058
Alicante, Fuenlabrada, Girona, Huelva, Las Palmas de GC, Madrid, Oviedo, Sagunto
2018-07-18
Active, closed
Eli Lilly and Company
Phase 3
533
Barcelona, Seville, Valencia, Valladolid
2018-03-14
Active, closed
Eli Lilly and Company
Phase 3
5,637
Córdoba, Barcelona, Santiago de Compostela, Lleida, Pozuelo de Alarcón, Alcorcón, Madrid, Málaga
2017-07-12
Active, closed
Eli Lilly and Company
Phase 1/2
857
Barcelona, Madrid
2017-05-02
Active, closed
Eli Lilly and Company
Phase 1
223
Barcelona, Madrid, Valencia
2016-11-21
Active, closed
Eli Lilly and Company
Phase 1
100
Ávila, Cáceres, Madrid
2016-11-14
Active, closed
Eli Lilly and Company
Phase 2
309
L'Hospitalet de Llobregat, Barcelona, Madrid
2016-05-19
Active, closed
Eli Lilly and Company
Phase 3
545
Barcelona, Hospitalet, Palma, Pozuelo de Alarcón, Madrid, Pamplona, Seville, Valencia
2015-05-06
Active, closed
Eli Lilly and Company
Phase 3
493
Badajoz, Barcelona, Donostia / San Sebastian, Lleida, Madrid, Valencia
2014-11-06
Active, closed
Eli Lilly and Company
Phase 3
453
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Valencia
2014-10-03
Active, closed
Eli Lilly and Company
Phase 3
669
Elche, Barcelona, Lleida, Madrid, Murcia, Valencia
2014-07-22
Active, closed
Eli Lilly and Company
Phase 2
110
Barcelona, Madrid
2012-05-22
Rows per page Showing 1–102 of 102
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-spain

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,909 studies in total at the last sync on 13 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 102 of those studies that match the filters currently applied.

How many clinical trials are recruiting in Spain?

46 of the 102 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:19 UTC sync. A further 4 have not yet opened recruitment, 50 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase, 102 studies
PhaseStudiesRecruitingShare
Phase 3612959.8%
Phase 122921.6%
Phase 212511.8%
Phase 1/2423.9%
Observational101%
Phase 2/3101%
Phase 4111%

Most active sponsors

Lead sponsors with the most studies
Lead sponsorStudiesRecruiting
Eli Lilly and Company10246

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Obesity (12) Overweight (11) Neoplasm Metastasis (10) Breast Cancer (6) Carcinoma, Non-Small-Cell Lung (6) Ulcerative Colitis (5) Breast Neoplasms (5) Advanced Solid Tumor (4) Endometrial Neoplasms (4) Metastatic Solid Tumor (3) Hypertension (3) Diabetes Mellitus, Type 2 (3) Crohn's Disease (3) Non-small Cell Lung Cancer (3) Ovarian Neoplasms (3)
→

Browse trials by site location

Barcelona (83) Madrid (68) Seville (38) Valencia (33) A Coruña (19) Málaga (19) Esplugues de Llobregat (13) Ferrol (13) Córdoba (11) Santiago de Compostela (10) Granada (10) Pamplona (9) Badajoz (9) Badalona (9) Pozuelo de Alarcón (8)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.